OS Therapies Inc (OSTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.88+3.30%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
OS Therapies aims to get OST-HER2 approved in 2026. It targets $50 million in OST-HER2 sales by 2027. The company expects $2 million in VAT refunds in 2Q 2026. It plans to keep enough cash to operate into 2027.
The company is losing money and sales are not proven yet. Recent capital raises and debt show cash needs. Earnings estimates remain negative through 2027. Approval delays or failures would hurt the outlook.
The market has sold off sharply, reflecting worries about cash and losses. No clear consensus revenue or price targets exist, so expectations are uncertain. Our view sees risk in execution and cash flow.
Breaks if: Cash runway insufficient to fund operations into 2027
Breaks if: OST-HER2 approval delayed beyond 2026 or denied in key regions
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on regulatory approvals and clinical trials. The current thesis is cautious due to volatility in management and the company's loss-making status.
The market seems to have low expectations for OSTX, reflected in its loss-making valuation. Investors may be pricing in the potential for continued challenges, especially if guidance is cut or if economic conditions worsen.
Fundamentals are likely to remain neutral in the near term, as the company has been missing expectations recently. Management is focused on securing regulatory approvals and advancing clinical trials, but execution remains mixed.
The long-term thesis hinges on the successful regulatory approvals for OST-HER2 and the initiation of its Phase 3 trial. Additionally, the performance of larger healthcare companies could influence sentiment and momentum for OSTX.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: OST-HER2 sales fall below $50 million in 2027
Breaks if: VAT refunds fall below $2 million in 2Q-26
In the next 1 to 3 years, OSTX's trajectory will depend on management's ability to execute on its priorities amidst a challenging environment. Not investment advice.